不同b值的表观弥散系数值对前列腺癌分期分级的诊断价值

doi:10.19558/j.cnki.10-1020/r.2021.01.013

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (2360 KB) RICH HTML
输出: BibTeX | EndNote (RIS)

摘要 目的: 探讨应用扩散加权成像（DWI）的表观弥散系数（ADC）值区分前列腺癌T分期高危组与低危组的价值。方法: 收集2016年1月—2018年4月217例前列腺癌患者的病例资料进行研究。所有患者均在GE 3.0T磁共振上获得图像,图像序列包含横轴位高分辨率T₂WI、DWI（b=0、1 000、2 000、3 000 s/mm²）,所有病例均有手术病理结果。由两名10年以上有前列腺疾病诊断经验的放射科医师分别对病灶进行ADC值的测量,并进行一致性和可重复性分析;对前列腺癌T分期高危组与低危组间的ADC值进行比较;利用ROC曲线对使用不同b值的ADC值区分前列腺癌T分期高、低危组的效能进行评价。结果: 前列腺癌病灶ADC值的一致性和可重复性极好,前列腺癌T分期高危组与低危组间ADC值有明显差别（P<0.05）。不同b值的ADC值能够区分T分期的高危组和低危组,但其效能无明显差别。结论: DWI的ADC值对区分前列腺癌T分期高低危组有一定帮助,可以在临床上起到辅助诊断的作用。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	张洪涛
	俞鸿凯
	郭勃毅
	王海屹
	白旭
	叶慧义

关键词 ：前列腺癌, T分期, 扩散加权成像, 表观弥散系数

Abstract：Objective: To investigate the value of ADC value in distinguishing high risk group and low risk group of T staging of prostate cancer. Methods: 217 eligible prostate cancer patients from January 2016 to April 2018 were enrolled in the study. The images of all patients were obtained on GE 3.0T MRI. The image sequences included axial high resolution T₂WI and DWI （b = 0, 1 000, 2 000 and 3 000 s/mm²）. The postoperative pathological results were obtained in all cases. The ADC values of prostate cancer lesions were measured by two prostate diagnostic physicians with more than ten-year experience, and consistency and repeatability analysis were done. The ADC values between high risk group and low risk group of T stage of prostate cancer were compared. The ROC curve was used to evaluate the ability of ADC values of different b values to distinguish the high and low risk groups of T stage of prostate cancer. Results: The consistency and repeatability of the ADC values of prostate cancer lesions measured by two physicians were excellent. There was significant difference in T stage of prostate cancer between high risk group and low risk group （P < 0.05）. The ADC value of different b value could distinguish the high and low risk groups of prostate cancer, but there was no significant difference in efficiency. Conclusions: ADC values provided some help for the judgment of high and low risk group of T stage of prostate cancer. ADC values between the two groups were statistically different.

Key words： prostate cancer T staging diffusion weighted imaging apparent diffusion coefficient

收稿日期: 2019-03-14

基金资助:国家自然科学基金面上项目（81771785）

通讯作者: 叶慧义,13701100368@163.com

引用本文:

张洪涛, 俞鸿凯, 郭勃毅, 王海屹, 白旭, 叶慧义. 不同b值的表观弥散系数值对前列腺癌分期分级的诊断价值[J]. 微创泌尿外科杂志, 2021, 10(1): 55-60.
ZHANG Hongtao, YU Hongkai, GUO Boyi, WANG Haiyi, BAI Xu, YE Huiyi. Classification of T staging of prostate cancer by ADC values of different b-value on DWI. JOURNAL OF MINIMALLY INVASIVE UROLOGY, 2021, 10(1): 55-60.

链接本文:

http://journal20.magtechjournal.com/Jwk_zgmnwk/CN/abstract/abstract1655.shtml 或 http://journal20.magtechjournal.com/Jwk_zgmnwk/CN/Y2021/V10/I1/55

[1] FENG TS, SHARIF-AFSHAR AR, WU J, et al.Multiparametric MRI improves accuracy of clinical nomograms for predicting extracapsular extension of prostate cancer. Urology, 2015,86(2):332-337.
[2] LAWRENCE EM, GALLAGHER FA, BARRETT T, et al.Preoperative 3-T diffusion-weighted MRI for the qualitative and quantitative assessment of extracapsular extension in patients with intermediate- or high-risk prostate cancer. AJR Am J Roentgenol, 2014,203(3):W280-W286.
[3] TAY KJ, GUPTA RT, BROWN AF, et al.Defining the incremental utility of prostate multiparametric magnetic resonance imaging at standard and specialized read in predicting extracapsular extension of prostate cancer. Eur Urol, 2016,70(2):211-213.
[4] MORLACCO A, SHARMA V, VIERS BR, et al.The incremental role of magnetic resonance imaging for prostate cancer staging before radical prostatectomy. Eur Urol, 2017,71(5):701-704.
[5] ROSENKRANTZ AB, REAM JM, NOLAN P, et al.Prostate cancer: utility of Whole-Lesion apparent diffusion coefficient metrics for prediction of biochemical recurrence after radical prostatectomy. AJR Am J Roentgenol, 2015,205(6):1208-1214.
[6] ENGELBRECHT MR, JAGER GJ, LAHEIJ RJ, et al.Local staging of prostate cancer using magnetic resonance imaging: a meta-analysis. Eur Radiol, 2002,12(9):2294-2302.
[7] TURKBEY B, ALBERT PS, KURDZIEL K, et al.Imaging localized prostate cancer: current approaches and new developments. AJR Am J Roentgenol, 2009,192(6):1471-1480.
[8] FÜTTERER JJ, ENGELBRECHT MR, HUISMAN HJ, et al. Staging prostate cancer with dynamic contrast-enhanced endorectal Mr imaging prior to radical prostatectomy: experienced versus less experienced readers. Radiology, 2005,237(2):541-549.
[9] TURKBEY B, PINTO PA, MANI H, et al.Prostate cancer: value of multiparametric Mr imaging at 3 T for detection--histopathologic correlation. Radiology, 2010,255(1):89-99.
[10] TAN CH, HOBBS BP, WEI W, et al.Dynamic contrast-enhanced MRI for the detection of prostate cancer: meta-analysis. AJR Am J Roentgenol, 2015,204(4):W439-W448.
[11] METZGER GJ, KALAVAGUNTA C, SPILSETH B, et al.Detection of prostate cancer: quantitative multiparametric Mr imaging models developed using registered correlative histopathology. Radiology, 2016,279(3):805-816.
[12] VOS EK, KOBUS T, LITJENS GJ, et al.Multiparametric magnetic resonance imaging for discriminating Low-Grade from High-Grade prostate cancer. Invest Radiol, 2015,50(8):490-497.
[13] FALETTI R, BATTISTI G, DISCALZI A, et al.Can DW-MRI, with its ADC values, be a reliable predictor of biopsy outcome in patients with suspected prostate cancer? Abdom Radiol, 2016,41(5):926-933.
[14] MIN BD, KIM WT, CHO BS, et al.Usefulness of a combined approach of t1-weighted, t2-weighted, dynamic contrast-enhanced, and diffusion-weighted imaging in prostate cancer. Korean J Urol, 2012,53(12):830-835.
[15] KIM CK, PARK SY, PARK JJ, et al.Diffusion-weighted MRI as a predictor of extracapsular extension in prostate cancer. AJR Am J Roentgenol, 2014,202(3):W270-W276.
[16] WOO S, CHO JY, KIM SY, et al.Extracapsular extension in prostate cancer: added value of diffusion-weighted MRI in patients with equivocal findings on T2-weighted imaging. AJR Am J Roentgenol, 2015,204(2):W168-W175.